Immunotherapy Improves PFS, OS in Endometrial Cancer
Results of a meta-analysis support the use of immunotherapy in combination with chemotherapy as initial treatment for advanced endometrial cancer, according to researchers.
Results of a meta-analysis support the use of immunotherapy in combination with chemotherapy as initial treatment for advanced endometrial cancer, according to researchers.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.
An abstract is unavailable.
The OncoAlert Newsletter is now out for June 23-29, 2023
Venture beyond current limits with our latest perspectives in ovarian cancer care. Learn about new treatments, improving patient outcomes.
A breast cancer breakthroughs fundraising event, where you’ll learn about the progress our dedicated physician-scientists have made for today’s patients and the discoveries they’re pursuing…
Walking is a simple exercise that has many health benefits. Karen Basen-Engquist, Ph.D., shares tips on walking as exercise and how to increase the amount…
Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.
An abstract is unavailable.